View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, March 17 (HealthDay News) -- Prophylactic treatment with 17-alpha-hydroxyprogesterone caproate (17Pc) in twin pregnancy does not reduce neonatal morbidity or prolong gestation, according to a study published in the March issue of the American Journal of Obstetrics & Gynecology.
C. Andrew Combs, M.D., Ph.D., from the Obstetrix Medical Group in Sunrise, Fla., and colleagues assessed whether prophylactic treatment with 17Pc reduced neonatal morbidity by prolonging pregnancy in 240 mothers carrying dichorionic-diamniotic twins. Participants were randomly divided into two groups: 160 received weekly 17Pc injections of 250 mg and 80 received placebo starting between weeks 16 and 24 of pregnancy and continuing until 34 weeks. Composite neonatal morbidity and gestational age were the main outcomes of the study.
The investigators found that the frequency of composite neonatal morbidity was similar in the 17Pc and placebo groups (14 and 12 percent, respectively). There was no significant difference in the mean gestational age at delivery between the two groups, but there was a significant difference in the median gestational age, with the duration in the placebo group three days longer. No perinatal deaths were reported in the 17Pc group but the placebo group had three deaths.
"Our findings add to a growing body of evidence that progestins are not effective for prevention of prematurity in multiple gestations," the authors write.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top